Monte Rosa Therapeutics, Inc. (GLUE)

5.45 -0.02 (-0.37%) At close: 04:00PM EDT

Monte Rosa Therapeutics, Inc.

321 Harrison Avenue
Suite 900
Boston, MA 02118
United States
(617) 949-2643
https://www.monterosatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 133

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Markus Warmuth M.D.	President, CEO & Director	901.35k	N/A	1972
Dr. Owen B. Wallace Ph.D.	Chief Scientific Officer	630.68k	N/A	1969
Dr. Filip Janku M.D., Ph.D.	Chief Medical Officer	658.66k	N/A	1975
Ms. Jennifer Champoux	Chief People & Operations Officer	N/A	N/A	N/A
Dr. Sharon Townson Ph.D.	Chief Technology Officer	N/A	N/A	1975
Dr. John C. Castle Ph.D.	Chief Data & Information Officer	N/A	N/A	1972
Mr. Andrew Funderburk	Senior VP and Head of IR & Strategic Finance	N/A	N/A	N/A
Mr. Philip Nickson J.D., Ph.D.	General Counsel	N/A	N/A	1979
Mr. Magnus Walter DPHIL	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Mr. Edmund Dunn	Vice President & Corporate Controller	N/A	N/A	1966

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Corporate governance

Monte Rosa Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.